Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROVIR: Favipiravir in non-critical hospitalized patients with COVID-19 pneumonia
2022-001387-10Phase 3Terminated
- Sponsor
- Tecnimede
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus pneumonia, acute respiratory illness (ARI) and coronavirus disease 2019 (COVID-19) comparing Favipiravir + standard of care with Placebo + standard of care (2 arms). Started Nov 2022; status: terminated.
02
Drugs
favipiravir
03
Conditions
coronavirus pneumoniaacute respiratory illness (ARI)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2022-001387-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001387-10.